<DOC>
	<DOCNO>NCT02886533</DOCNO>
	<brief_summary>Prospective , multicenter , observational study three-year inclusion period ( January 1 , 2012 December 31 , 2015 ) 6-month follow-up</brief_summary>
	<brief_title>Major Bleeding Risk Associated With Antithrombotics</brief_title>
	<detailed_description>All adult subject live five well-defined area affiliate French National Health Insurance System least one reimbursement antithrombotic 3-year study period identify use data National Health reimbursement database ( Système National d'Information Inter-Régimes de l'Assurance Maladie , SNIIR-AM ) . SNIIR-AM contains individualize , anonymous comprehensive data health spending reimbursement affiliated subject , include basic patient demographic data , medical drug well outpatient medical care , prescribe perform health-care professional public private practice . This allow calculate denominator ( number person-years anti-thrombotic drug exposure ) . Crude incidence rate major bleed per 100 person-months calculate antithrombotic user , anticoagulant others ; stratification modify HAS-BLED score allow fair comparison anti-thrombotic drug class .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Patient major bleed event associate antithrombotic drug Patient old 18 year old Information 1 6month followup give pending nonopposition letter Patients major bleed event associate antithrombotic hospitalization Patients intentional overdose antithrombotic drug Patients multitrauma Patients live outside define influence area five participate city</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Major haemorrhage</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Antiplatelet drug</keyword>
	<keyword>Gastrointestinal bleeding</keyword>
	<keyword>Intracranial haemorrhage</keyword>
</DOC>